Drug Trial Radar · NCT02970305
Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)
Last checked: Nov 20, 2026Latest source record: Dec 22, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
403
Actual
Start
Nov 4, 2016
Primary completion
Oct 16, 2019
Study completion Oct 28, 2019
Sponsor
- Lead sponsor
- ACADIA Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 22, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and safety of adjunctive pimavanserin compared with adjunctive placebo in the treatment of the negative symptoms of schizophrenia
Conditions
- Schizophrenia
Interventions
PimavanserinDrug
Pimavanserin 34 mg, 20 mg, or 10 mg, taken as two tablets, once daily by mouth
PlaceboDrug
Placebo, taken as two tablets, once daily by mouth
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Week 26 in the Negative Symptom Assessment-16 (NSA-16) Total ScoreTime frame: From baseline to Week 26
Locations
101 sites in 10 countries. Site status is shown where the registry gives one.
Site not named
Phoenix, Arizona
Site not named
Rogers, Arkansas
Site not named
Bellflower, California
Site not named
Lemon Grove, California
Site not named
Norwalk, California
Site not named
San Diego, California
Site not named
San Diego, California
Site not named
Santa Ana, California
Site not named
Torrance, California
Site not named
Hialeah, Florida
Site not named
Lauderhill, Florida
Site not named
Miami, Florida
Site not named
Miami, Florida
Site not named
Tampa, Florida
Site not named
Atlanta, Georgia
Site not named
Atlanta, Georgia
Site not named
Decatur, Georgia
Site not named
Marietta, Georgia
Site not named
Chicago, Illinois
Site not named
Hoffman Estates, Illinois
Site not named
Wichita, Kansas
Site not named
Ann Arbor, Michigan
Site not named
Las Vegas, Nevada
Site not named
Berlin, New Jersey
Site not named
Albuquerque, New Mexico
Site not named
Rochester, New York
Site not named
Charlotte, North Carolina
Site not named
Durham, North Carolina
Site not named
Oklahoma City, Oklahoma
Site not named
Downingtown, Pennsylvania
Site not named
Charleston, South Carolina
Site not named
Irving, Texas
Site not named
Richardson, Texas
Site not named
Plovdiv, Bulgaria
Site not named
Sofia, Bulgaria
Site not named
Sofia, Bulgaria
Site not named
Sofia, Bulgaria
Site not named
Sofia, Bulgaria
Site not named
Targovishte, Bulgaria
Site not named
Tserova Koria, Bulgaria
Showing 40 of 101 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.